Daniel is a biochemist with broad expertise in the biomedical sciences, including gene therapies, gene editing, RNA biology, and protein folding. He holds a Ph.D. in Chemistry from the University of California, Berkeley, and was a Damon Runyon Cancer Research fellow at The Johns Hopkins University School of Medicine. As CSO and co-founder of Constantiam Biosciences, Daniel is focused on bringing powerful new methods to the challenge of interpreting human genetic variation.